New schizophrenia drug shows promise in early trial
NCT ID NCT06179108
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called LB-102 in 359 adults with acute schizophrenia. Participants received either LB-102 or a placebo for 28 days. The goal was to see if LB-102 reduces symptoms like hallucinations and confusion better than a placebo. The trial is now complete, and results will show if LB-102 is safe and effective enough to move to larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LB-102 (a drug that blocks certain brain receptors linked to schizophrenia symptoms)
What this could lead to
If successful, LB-102 could offer a new treatment option for acute schizophrenia, potentially improving symptoms like hallucinations and delusions.
What could go wrong
This is an early Phase 2 trial with only 359 people. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Behavioral Clinical Research, Inc.
Hollywood, Florida, 33021, United States
-
CelExel CNS
Garden Grove, California, 92845, United States
-
CelExel Clinical Innovations
Bellflower, California, 90706, United States
-
CenExel ACMR
Atlanta, Georgia, 30331, United States
-
CenExel CBH
Gaithersburg, Maryland, 20877, United States
-
CenExel CIT Riverside
Riverside, California, 92506, United States
-
CenExel HRI
Berlin, New Jersey, 08009, United States
-
CenExel RCA
Hollywood, Florida, 33024, United States
-
CenExel iResearch
Decatur, Georgia, 30030, United States
-
Community Clinical Research
Austin, Texas, 78754, United States
-
InSite Clinical Research
DeSoto, Texas, 75115, United States
-
Midwest Clinical Research Center
Dayton, Ohio, 45417, United States
-
NRC Research Institute
Santa Ana, California, 92705, United States
-
Neuro-Behavioral Clinical Research
North Canton, Ohio, 44720, United States
-
Pillar Clinical Research
Bentonville, Arkansas, 72712, United States
-
Pillar Clinical Research
Chicago, Illinois, 60641, United States
-
Pillar Clinical Research
Richardson, Texas, 75080, United States
-
ProScience Research Group
Culver City, California, 90230, United States
-
Richmond Behavioral Associates
Staten Island, New York, 10314, United States
-
Segal Institute for Clinical Research
Miami Lakes, Florida, 33016, United States
-
Synergy Research
Lemon Grove, California, 91945, United States
-
Synexus
Cerritos, California, 90703, United States
-
Uptown Research Institute
Chicago, Illinois, 60640, United States
-
Woodland Internation Research Group
Little Rock, Arkansas, 72211, United States
-
Woodland Research Northwest
Rogers, Arkansas, 72758, United States